Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle.